Incyte Corporation
INCY Healthcare Biotechnology
Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.
Follow INCY
Incyte Corporation (INCY) EPS (diluted)
Incyte Corporation's EPS (diluted) for fiscal 2025 was $6.41, up 4,173.3% from $0.15 in fiscal 2024. Over the twelve months to 30 June 2026 it was $7.85. Over the past ten years it has ranged from −$1.53 (fiscal 2017) to $6.41 (fiscal 2025) — the current reading is the highest in ten years. Incyte Corporation ranks 27th of 603 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $6.41 | 4,173.33% |
| FY2024 | $0.15 | (94.34%) |
| FY2023 | $2.65 | 74.34% |
| FY2022 | $1.52 | (64.40%) |
| FY2021 | $4.27 | — |
| FY2020 | −$1.36 | — |
| FY2019 | $2.05 | 301.96% |
| FY2018 | $0.51 | — |
| FY2017 | −$1.53 | — |
| FY2016 | $0.54 | 1,700.00% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $2.81 | 91.16% |
| Mar 2026 | $1.47 | 0.68% |
| Dec 2025 | $1.46 | (30.81%) |
| Sep 2025 | $2.11 | 3.43% |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ASND Ascendis Pharma A/S compare | $12.89 |
| INCY Incyte Corporation | $7.85 |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $5.76 |
| EXEL Exelixis, Inc. compare | $3.18 |
| RPRX Royalty Pharma PLC compare | $1.45 |
| GMAB Genmab A/S Sponsored ADR compare | $1.27 |
| ROIV Roivant Sciences Ltd. compare | −$0.29 |
| INSM Insmed, Inc. compare | −$4.11 |
| BNTX BioNTech SE Sponsored ADR compare | −$7.83 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on INCY
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement